ClinicalTrials.gg
RecruitingNCT07559019Updated Jun 4, 2026

Safety and Preliminary Activity of BI115 in Advanced SCLC

A Phase 1 interventional study of IBI115 in Small Cell Lung Cancer (SCLC), sponsored by Innovent Biologics (Suzhou) Co. Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Innovent Biologics (Suzhou) Co. Ltd. (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 365 studies in Small Cell Lung Carcinoma with a site in China — 183 open to participants now, 215 under way, 36 of them phase 3. Small Cell Lung Carcinoma · China.

Planned enrollment
105th of 333
150 · median 63
Started
2026
with 48 others
Phase 1
43 of 365
24 open now
Primary completion
2028-02
later than 150 of 214 live
Registered
342nd of 365
by date

Among the 365 studies in Small Cell Lung Carcinoma with a site in China, this one is the 105th largest by planned enrollment of the 333 interventional ones that give a count, is one of 49 that started in 2026, is one of 43 in phase 1, reaches primary completion later than 150 of the 214 other live ones, and was the 342nd registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 366 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

183 of the 365 studies in Small Cell Lung Carcinoma with a site in China are open now. Recruiting first, the newest first:

177 more — sign in →

All 183 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 266 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 365 studies in Small Cell Lung Carcinoma with a site in China, or all of them as a file.
02

Study summary

This study is a multi-regional, open-label phase I study to evaluate the Safety, Tolerability, and Efficacy of IBI115 as Monotherapy and in Combination Therapy in Participants with Advanced Small Cell Lung Cancer

03

Conditions studied

  • Small Cell Lung Cancer (SCLC)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants must be able to understand and sign the written form for participation in this trial, including all evaluations and procedures specified in this protocol.
  2. Male or female participants aged ≥18 years and ≤75 years.
  3. Participants with or cytologically confirmed advanced small cell lung cancer.
  4. At least one according to V1.1 within 28 days prior to the first dose of IBI115.
  5. (ECOG) performance status score of 0-1.
  6. Expected survival period ≥12 weeks.
  7. Adequate bone marrow and organ function confirmed during the screening period.

Exclusion criteria

Exclusion Criteria:

  1. Concurrent participation in another interventional clinical study, except for observational non-interventional studies or being in the survival follow-up phase of an interventional study.
  2. Administration of a within 4 weeks prior to the first dose of the study drug or a cancer vaccine within 3 months prior, or planning to receive any live vaccine during the study period.
  3. Adverse reactions from prior anti-tumor therapy that have not resolved to v6.0 Grade 0, Grade 1, or baseline levels by the time of the first dose of the study drug.
  4. Known or intolerance to IBI115, sintilimab, or any of their .
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    IBI115

    Subjects will receive IBI115 therapy until disease recurrence, unacceptable toxicity, receiving new anti-tumor therapy, withdrawal of informed consent (ICF), lost to follow-up or death, or other conditions that require treatment discontinuation (whichever occurs first). The maximum duration of treatment with IBI115 is 24M.

    Drug: IBI115

Interventions

  • DrugIBI115

    IBI115 will be administered. The Dose Limiting Toxicity (DLT) observation period will last for 28 or 21 days after first dose. After completion of the DLT observation period, subject will continue to receive IBI115 until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal od consent for study participation, end of the study, or for a maximum of 24 months, whichever occurs first.

06

What researchers measure

Primary outcomes

  1. Number of participants with Adverse Events (AE), Serious Adverse Events (SAE) and treatment emergent adverse events (TEAE)

    Safety Features including Adverse Events (AE), Serious Adverse Events (SAE) and treatment emergent adverse events (TEAE).

    Time frame: up to 90 days after the last administration

  2. Dose-limiting toxicity (DLT)

    DLTs will be assessed during the DLT observation period to determine maximum tolerated dose (MTD) ) and/or recommended dose for combination (RDC).

    Time frame: up to 28 days after the first dose of IBI115

  3. MTD of IBI115

    to determine MTD of IBI115

    Time frame: up to 90 days after the last administration

  4. RDC of IBI115

    to determine RDC of IBI115

    Time frame: up to 90 days after the last administration

  5. Number of participants with clinically significant changes in physical examination results

    A complete physical examination will include: general appearance, respiratory, cardiovascular, abdomen, skin, head and neck (including ears, eyes, nose, and pharynx), lymph nodes, thyroid, musculoskeletal (including spine and extremities), genital/anal, and neurological assessments, if indicated. Clinically significant abnormal findings at screening will be recorded as medical history or AE based on the investigator's analysis and judgment.

    Time frame: up to 90 days after the last administration

  6. Number of participants with abnormal vital signs

    Collection of vital signs will include body temperature, heart rate, respiratory rate, blood pressure, and oxygen saturation.

    Time frame: up to 90 days after the last administration

Secondary outcomes

  1. Area under the concentration-time curve (AUC)

    an element to assess the pharmacokinetics (PK) profile of IBI115

    Time frame: Up to 7 days after the last administration

  2. Peak plasma concentration

    an element to assess the PK profile of IBI115

    Time frame: Up to 7 days after the last administration

  3. Time to peak concentration

    an element to assess the PK profile of IBI115

    Time frame: Up to 7 days after the last administration

  4. Clearance (CL)

    an element to assess the PK profile of IBI115

    Time frame: Up to 7 days after the last administration

  5. Apparent volume of distribution (V)

    an element to assess the PK profile of IBI115

    Time frame: Up to 7 days after the last administration

  6. Half-life (T1/2)

    an element to assess the PK profile of IBI115

    Time frame: Up to 7 days after the last administration

  7. Incidence of anti-drug antibodies (ADA)

    an element to assess the immunogenicity profile of IBI115

    Time frame: Up to 7 days after the last administration

  8. Incidence of neutralizing antibodies (NAb) (if applicable)

    an element to assess the immunogenicity profile of IBI115

    Time frame: Up to 7 days after the last administration

  9. Objective response rate (ORR)

    based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Through study completion, up to 2 years

  10. Duration of response (DoR)

    based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Through study completion, up to 2 years

  11. Tisease control rate (DCR)

    based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Through study completion, up to 2 years

  12. Time to response (TTR)

    based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Through study completion, up to 2 years

  13. Progression-free survival (PFS)

    based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1

    Time frame: Through study completion, up to 2 years

  14. Overall survival (OS)

    Overall survival (OS)

    Time frame: Through study completion, up to 2 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Feb 2028, 21 months after the start.

Of 111 industry-sponsored phase 1 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 63. This study's planned 21 months is below that.

Counting every sponsor, half of 143 studies reached it within 46 months; a quarter within 29 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2026
First posted
Apr 30, 2026
StartActual
May 21, 2026
Primary completionEst.
Feb 29, 2028
CompletionEst.
Mar 30, 2030
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07559019
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
May 21, 2026
Primary completion
Feb 29, 2028 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Jun 4, 2026

Study contacts

Xiao Zhang
Contact
kobe.zhang@innoventbio.com
+86 021 3183 7200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion